Молекулярно-генетическое исследование хронического миелолейкоза
Диссертация
При анализе экспрессии гена переносчика органических катионов hOCTl в лейкоцитах периферической крови выявлены статистически значимые различия в уровне экспрессии между контрольной группой (M±se:l, 379±0,3732) и больными XMJI с высокой экспрессией BCR-ABL (M±se:2,492±0,3842) — р=0,01, а также между контрольной группой и больными с полным молекулярным ответом (M±se:2,275±0,3962) — р=0,03. Как… Читать ещё >
Список литературы
- Аксенова Е.В., Крутов A.A., Солдатова И. Н., Ахлынина Т. В., Лапшина H.A., Мисюрин A.B. Стандартизация молекулярной диагностики хронического миелолейкоза // Клиническая онкогематология, 2010, № 2, С.160−165.
- Виноградова О. Ю. Клиническая эволюция хронического миелолейкоза в процессе лечения ингибиторами тирозинкиназ // Автореферат диссертации доктора мед. наук. М., 2011.
- Виноградова О.Ю., Туркина А. Г., Хорошко Н. Д. Организация терапии хронического миелолейкоза. Первый общероссийский регистр больных хроническим миелолейкозом: анализ и перспективы // Гематология и трансфузиология. 2008. — Т. 53, № 5. — С. 54−58.
- Волкова М.А. Гливек революция в терапии хронического миелолейкоза // Фарматека. -2003. — Т.77, № 14. — С. 39−47.
- Волкова М.А. Клиническая онкогематология: руководство для врачей. -2-е изд., перераб. и доп. М.: Медицина. — 2007. — С.1120.
- Волкова М.А. Новые возможности в терапии хронического миелолейкоза: дазатиниб // Клиническая онкогематология: фундаментальные исследования и клиническая практика. 2008. — Том 1, № 3.-С. 218−226.
- Воробьев А.И. Лейкозы: проблемы и достижения // Клин, фармакология и терапия. 1995. — Т. 4, № 4. — С. 16−17.
- Галицкий В.А. Гипотеза о механизме инициации малыми РНК метилирования ДНК de novo и аллельного исключения // Цитология. -2008. 50(4): 277−286.
- Давыдов М.И., Аксель Е. М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2007 г. // Вестник РОНЦ им. H.H. Блохина РАМН. 2009. — Т. 20, № 3 (прил. 1). — С.52−90.
- Дубина М.В., Куевда Д. А., Хомякова Т. Е., Цаур Г. А., Куцев С. И., Зарицкий А. Ю. Молекулярный мониторинг эффективности терапии больных хроническим миелолейкозом в России // Современная онкология № 4. 2010. — Т. 12. — С. 11−17.
- П.Копнин Б. П. Мишени действия онкогенов и опухолевых супрессоров: ключ к пониманию базовых механизмов канцерогенеза // Биохимия. -2000.-65.-С. 5−33.
- Копнин Б.П. Опухолевые супрессоры и мутаторные гены. В кн: Канцерогенез. Москва // Медицина. 2004:125−156.
- Куцев С.И. Генетический мониторинг таргетной терапии хронического миелоидного лейкоза // Автореферат диссертации доктора мед. наук. -М., 2009.
- Куцев С.И., Вельченко М. В. Значение анализа мутаций гена BCR-ABL в оптимизации таргетной терапии хронического миело лейкоза // Клиническая онкогематология. 2008а. — Т. 1, № 3. — С. 190−199.
- Куцев С.И., Вельченко М. В., Зельцер А. Н. Молекулярно-генетический мониторинг терапии хронического миелолейкоза ингибиторами тирозинкиназ // Онкогематология. 2008b. — № 4. — С. 17−25.
- Куцев С.И., Вельченко М. В., Морданов C.B. Роль мутаций гена BCR-ABL в развитии рефрактерности к иматинибу у пациентов с хроническим миелолейкозом // Клиническая онкогематология. 2008с — Т.1, № 4. — С. 303−309.
- Мисюрин A.B., Аксенова Е. В., Крутов A.A. и соавт. Молекулярная диагностика хронического миелолейкоза // Гематол трансфузиол. 2007. -2:35−40.
- Рогаев Е.И., Боринская С. А., Исламгулов Д. В., Григоренко А. П. МикроРНК человека в норме и патологии // Молекулярная биология. -2008. Т.42, № 5. — С.751−764.
- Телегеев Г. Д. и соавт. Роль белка BCR-ABL в лейкозогенезе // Экспериментальная онкология. 1999. — Том 21. — 182−194.
- Туркина А.Г. Ингибитор сигнальных путей STI 571 (Signal Transductor Inhibitor) новое направление в лечении хронического миелолейкоза // Современная Онкология. — 2001. — Том 3, № 2. — С. 46−48.
- Туркина А.Г., Челышева Е. Ю. Цитогенетический и молекулярный ответ — ранние маркеры эффективности терапии Гливеком больных Ph±хроническим миелолейкозом. Фарматека 2004- 18(95).
- Челышева Е.Ю., Туркина А. Г., Мисюрин А. В., Захарова А. В. Раннее выявление цитогенетического рецидива при динамическом исследовании уровня BCR-ABL-транскрипта у больного хроническим миелолейкозом // Гематол трансфузиология. 2007. — 2:50−51.
- Четверина Е.В., Четверин А. Б. Наноколонии и диагностика онкологических заболеваний, ассоциированных с хромосомными транслокациями // Успехи биологической химии. 2010. — 50. — С. 387 446.
- Шнайдер Н. А. Нейрофиброматоз 1-го типа: этиопатогенез, клиника, диагностика, прогноз // Международный неврологический журнал. -2007.-№ 5 (15)-С. 162−168.
- Abram C.L., Courtneidge S.A. Src family tyrosine kinases and growth factor signaling // Exp Cell Res. 2000. — Vol.254, № 1. — P. 1−13.
- Allan N., Richards S., Shepherd P. et al. Medical Research Council randomized multicenter trial of interferon a nl for chronic myeloid leukemia // Lancet. 1995.-345.- 1392.
- Baccarani M., Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet // Blood. 2006. — Vol.108. -P. 1809- 1820.
- Baccarani M., Castagnetti F, Gugliotta G, et al. Response definitions and European Leukemianet Management recommendations // Best Pract Res Clin Haematol. 2009. — Vol. 22. — P.331−341.
- Barnes D.J., Palaiologou D., Panousopoulou E., et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia // Cancer Res. 2005. — Vol.65, № 19. — P.8912−8919.
- Berezikov E. et al. Phylogenetic shadowing and computational identification of human microRNA genes // Cell. 2005. — 120:21−24.
- Biernaux C., Loos M., Seis A., Huez G., Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals // Blood. 1995. Vol.86. — P.3118−3122.
- Bloomston M., Frankel W.L., Petrocca F., et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis // JAMA. 2007. — 297:1901−1908.
- Borrow J. Guidelines for Mutation Analysis of BCR/ABL Kinase Domain // WMRGL. 2007. — P. 1−32.
- Bostjancic E., Glavac D. Importance of microRNAs in skin morphogenesis and diseases // Acta Dermatovenerol Alp Panonica Adriat. 2008. — 17 (3): 95−102.
- Boyd S.D. Everything you wanted to know about small RNA but were afraid to ask // Lab Invest. 2008. — Vol.88. — P.569−578.
- Branford S., Hughes T.P., Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics // Br J Haematol. 1999. — Vol.107. — P.587−599.
- Braun B.S., Shannon K. Targeting Ras in myeloid leukemias // Clin Cancer Res.-2008.- 14:2249−52.
- Brendel C., Scharenberg C., Dohse M., et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells // Leukemia. 2007. — 21:1267−1275.
- Brodeur G.M. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes // N Engl J Med. 1994. — 330:637−638
- Buchberg A.M., Cleveland L.S., Jenkins N.A., et al. Sequence homology shared by neurofibromatosis type 1 gene and IRA-1 and IRA-2 negative regulators of the Ras cyclic AMP pathway // Nature. 1990. — 347:291−294.
- Burger H, vanTol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump // Blood. 2004. — 104:2940−2942.
- Cacev T., Radosevic S., Spaventi R., Pavelic K., Kapitanovic S. NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer // Colon cancer. 2005. — 54:1129−1135.
- Calabretta B., Perrotti D. The biology of CML blast crisis // Blood. 2004. -Vol.103, № 11.- P.4010−4022.
- Calin G.A. et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13ql4 in chronic lymphocytic leukemia // Proc.Natl.Acad.Sci.U.S.A. 2002. — 99:15 524−15 529.
- Cawthon RM, Weiss R, Xu GF, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations // Cell. 1990. — 62:193−201.
- Chen C., Zhang Y., Zhang L., Weakley S.M., Yao Q. MicroRNA-196: critical roles and clinical applications in development and cancer // J Cell Mol Med. -2011.- 15(l):14−23.
- Chen K., Rajewsky N. Natural selection on human microRNA binding sites inferred from SNP data // Nature Genetics. 2006. — 38. — P.1452−1456.
- Cheng, A.M., Byrom, M.W., Shelton, J., Ford, L.P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis // Nucleic Acids Res. 2005. — 33:1290−1297.
- Corbin A., La Rose P., Stoffregen E. et al. Several BCR-ABL kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib // Blood. 2003. — 101(11):4611−4614.
- Cortes J. Natural history and staging of chronic myelogenous leukemia // Hematol Oncol Clin North Am. 2004. -Vol.18. — P.569−584.
- Crossman L.C., Druker B.J., Deininger M.W., et al. hOCT 1 and resistance to imatinib // Blood. 2005. — Vol.106, № 3. — P. 1133−1134.
- Danhauser-Riedl S., Warmuth M., Druker B.J., et al. Activation of Src kinases p53/561yn and p59hck by p210bcr/abl in myeloid cells // Cancer Res. 1996. — Vol.56, № 1. — P.3589−3596.
- Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs // Chem Rev. 2009. — 109:2989−3011.
- Eis P. S. et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas // Proc.Natl.Acad.Sci.USA. 2005. — 102:3627−3632.
- Faber J., Gregory R., Armstrong S. Linking miRNA Regulation to BCR-ABL Expression: The Next Dimension // Cancer Cell. 2008. — Vol.13. — P.467−469.
- Fausel C. Targeted Chronic Myeloid Leukemia Therapy: Seeking a Cure // J Manag Care Pharm. 2007. — Vol.13, № 8. — Suppl S-a:S8-S12.
- Fukada T., Tonks N.K. The reciprocal role of Egr-land Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-tyrosine kinase // JBiol Chem. 2001. — 276:25 512:9.
- Furukawa T., Sunamura M., Horii A. Molecular mechanisms of pancreatic carcinogenesis // Cancer Sci. 2006. — 97:1−7.
- Gillet J.P., Efferth T., Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes // Biochim Biophys Acta. 2007. -1775:237−262.
- Goldman J., Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? // Leuk. Lymphoma. 2006. — Vol.47. — P. 1−7.
- Goldman J.M. Chronic myeloid leukemia-still a few questions // Exp Hematol. -2004.-32:2−10.
- Gorre M., Mohammed M., Ellwood K. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification // Science. 2001. — 293:876−880.
- Graham S.M., Jorgensen H.G., Allan E., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro // Blood. 2002. — Vol.99, № 1. — P.319−325.
- Griffiths-Jones S. et al. miRBase: microRNA sequences, targets and gene nomenclature // Nucleic Acids Res. 2006. — 34:140−144.
- Gromicho M., et al. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1 // Leukemia & Lymphoma. 2011. — 52 (10): 1980−1990.
- Guilhot F., Chastang C., Michallet M. et al. Interferon-alfa 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia // N Engl J Med. 1997.-337.-223.
- Haj F.G., Verveer P.J., Squire A., Neel B.G., Bastiaens P.I. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum // Science. 2002. — 295. — 1708−1711.
- Hao Y. et al. Tumour-suppressor activity of H19 RNA // Nature. 1993. -365:764−767.
- Hehlmann R., Heimpel H., Hasford J., et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea // Blood. 1993. — Vol. 82. — P. 398.
- Heisterkamp N., Stam D., Groffen J. et al. Structural organization of the bcr gene and its role in the Ph' translocation // Nature. 1985. — 315:758−761.
- Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy // Leukemia. 2002. -Vol.16, № 11.-P.2190−2196.
- Hochhaus A., O’Brien S.G., Guilhot F., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia // Leukemia. 2009. — 23:1054−1061.
- Hornstein E., Mansfield J.H., Yekta S., et al. The microRNA miR-196 acts upstream of Hoxb8 and Shh in limb development // Nature. 2005. — 438: 671−674.
- Houghton P.J., Germain G.S., Harwood F.C., et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro // Cancer Res. 2004. — 64:2333−2337.
- Hu Y., Liu Y., Pelletier S., et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia // Nat Genet. 2004. — Vol.36, № 5. — P.453−461.
- Hughes T., Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia // Blood Reviews. 2006. -20:29−41.
- Hui A.B., Shi W., Boutros P.C., et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues // Lab Invest. -2009. 89:597−606.
- Jha C.B., Kucheria K., Choudhary V.P. Diagnostic role of conventional cytogenetics and fluorescence in situ hybridization (FISH) in chronic myeloid leukemia patients // Kathmandu Univ Med J (KUMJ). 2006. — Vol.4, № 2. -P.171−175.
- Johansson B., Fioretos T., Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia // Acta Haematol. 2002. — Vol.107, № 2. — P.76−94.
- Jordanides N.E., Jorgensen H.G., Holyoake T.L., et al. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate // Blood. 2006. — Vol. 108, № 4. — P.1370−1373.
- Kaeda S.A., Chase A., Goldman J.M. Cytogenetic and molecular monitoring of residual desease in chronic myeloid leukemia // Acta Hematol. 2002. -107:64−75.
- Kantarjian H., O’Brien S., Shan J., et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions // Cancer. 2008. — Vol. 112 (4): 837−845.
- Kawasaki H., Taira K. MicroRNA-196 inhibits HOXB8 expression in myeloid differentiation of HL60 cells // Nucleic Acids Symp Ser. 2004. — 48:211 212.
- Komarova N.L., Wodarz D. Effect of cellular quiescence on the success of targeted CML therapy // PLoS ONE. 2007. — Vol.2, № 10. — E990.
- Konopka J.B., Watanabe S.M., Witte O.N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity // Cell. 1984. Vol.1, № 37. — P.1035−1042.
- Koyama N., Koschmieder S., Tyag S. et. al. Inhibition of Phosphotyrosine Phosphatase IB Causes Resistance in. BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571. Clin Cancer Res 2006- 12:2025−2031
- Krumlauf R. Hox genes in vertebrate development // Cell. 1994. — 78: 191−201.
- Kurzrock R., Bueso-Ramos C.E., Kantarjian H., Freireich E., Tucker S.L., Siciliano M., et al. BCR rearrangement-negative chronic myelogenous leukemia revisited // J Clin Oncol. 2001. Vol.19. — P.2915−2926.
- Kurzrock R., Guttrman J.U., Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias // N. Engle. J. Med.-1988.-Vol.319.- P.990−8.
- Kurzrock R., Kantarjian H., Druker B., Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics // Annals of internal medicine. 2003. — Vol.138. — P.819−830.
- Lage H. An overview of cancer multidrug resistance: a still unsolved problem // Cell Mol Life Sei. 2008. — 65:3145−3167.
- Lai EC. et al. Computational identification of Drosophila microRNA genes // Genome Biol. 2003. — 4, R42.
- LaMontagne K.R. Jr., Hannon G., Tonks N.K. Protein tyrosine phosphatase PTP1B suppresses p210 bcrabl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells // Proc Natl Acad Sei USA. 1998. -95:14 094:9.
- LaMontagne K.R., Jr., Flint AJ, Franza BR, Jr., Pandergast AM, Tonks NK. Protein tyrosine phosphatase IB antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo // Mol Cell Biol. 1998. — 18:2965:75.
- LaMontagne K.R., Jr., Hannon G., Tonks N.K. Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells // Proc. Natl. Acad. Sei. U.S.A. -1998. 14 094−14 099.
- Larson R. A., Druker B. J., Guilhot F. et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study // Blood. 2008. — 111:4022−4028.
- Laurent E., Talpaz M., Kantarjian H., Kurzrock R. The BCR gene and Philadelphia chromosome-positive leukemogenesis // Cancer Res. 2001. -Vol.61.-P.2343−2355.
- Le Coutre P., Kreuzer K.A., Pursche S., et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 // Cancer Chemother Pharmacol. 2004. — Vol.53, № 4. — P.313−323.
- Lepper E.R., Nooter K., Verweij J., Acharya M.R., Figg W.D., Sparreboom A. Mechanism of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2 // Pharmacogenomics. 2005. — Vol.6.- P.115−138.
- Lessard L., Stuible M., Tremblay M.L. The two faces of PTP1B in cancer // Biochim Biophys Acta. 2010. — 1804(3):613−619.
- Li Y., O’Connel P., Huntsman H., et al. Genomic organisation of the neurofibromatosis 1 gene (NF1)// Genomics. 1995. -25:9−18.
- Li Y., Zhang M., Chen H., et al. Ratio of miR-196s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis // Cancer Res. -2010.-70:7894−904.
- Livak K.J., Schmittgen T.D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2A (-AACt) Method // METHODS.- 2001. V.25. -P.402−408
- Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products // Science. -1990. -Vol.247. P. 1079−1082.
- Machova Polakova K., Lopotova T., Klamova H., Burda P., Trneny M., Stopka T., Moravcova J. Expression patterns of microRNAs associated with CML phases and their disease related targets // Mol Cancer Res. 2009. -7(10):1693−1703.
- Mahon F.X., Hayette S., Lagarde V., et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression // Cancer Res. 2008. — 68:9809−9816.
- Marin D., Marktel S., Szydlo R. et al. Survival of patients with chronic phase chronic myeloid leukemia after failed response to interferon-alfa // Lancet. 2003. — 362:617−619.
- Mathew C.C. The isolation of high molecular weight eucariotic DNA // Methods in molecular biology / Ed. Walker J.M. N.Y.- Haman press. 1984. -V.2. — P.31−34.
- Mayer B.J., Baltimore D. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase // Mol Cell Biol. 1994. -14:2883.
- Melo J.V. Imatinib and ABCG2: who controls whom? // Blood. 2006. -108:1116−1117.
- Metzler M. et al. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma // Genes Chromosomes Cancer. 2004. — 39: 167−169.
- Michael M.Z. et al. Reduced accumulation of specific microRNAs in colorectal neoplasia // Mol. Cancer Res. 2003. — 1:882−891.
- Miething C., Mugler C., Grundler R., et al. Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo // Leukemia. 2003. — 17:169:9.
- Momparler R.L., Cote S., Eliopoulos N. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia // Leukemia. 1997. — Vol.11. — P.175−180.
- Nagar B., Bornmann W.G., Pellicena P., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) // Cancer Res. 2002. — Vol.62, № 15. -P.4236−4243.
- Nishimura T., et al. Total number of genome alterations in sporadic gastrointestinal cancer inferred from pooled analyses in the literature, Tumour Biol. 29 (2008) 343−350.
- Nishizaki T., Ozaki S., Harada K., Ito H., Arai H., Beppu T., Sasaki K. Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization // Genes Chromosomes Cancer. 1998.-21:340−346.
- Nowell P.C. Discovery of the Philadelphia chromosome: a personal perspective // Journal of Clinical Investigation. 2007. — Vol. 117 (8). — P. 2033−2035.
- Nowell P.C., Hungerford, D.A. A minute chromosome in chronic granulocytic leukemia // Science. 1960. — Vol. 132. — P. 1488−1501.
- O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia // N Engl J Med. 2003. — 348 (11): 994−1004.
- O’Hare T., Eide C.A., Deininger M. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia // Blood 2007. 110(7):2242−9.
- Okabe S., Tauchi T., Ohyashiki K. Characteristics of dasatiniband imatinib-resistant chronic myelogenous leukemia cells // Clin Cancer Res. 2008. -14:6181−6186.
- Pasternak G., Hochhaus A., Schultheis B., Hehlmann R. Chronic myelogenous leukemia: molecular and cellular aspects // J. Cancer Res. Clin. Oncol. 1998. — Vol. 12. — P.643−60.
- Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving p210 bcr-abl-transduced bone marrow // Blood. 1998. -Vol.92. -P.3780−3792.
- Pehlivan M., Sercan Z., Sercan H.O. sFRPl promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia // Leukemia Research. 2008. — Vol.33, № 8. — P.1062−1067.
- Picard S., Titier K., Etienne G. et al. Though imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia // Blood. 2007. — Vol. 109:3496−3499.
- Pushparaj P.N., Melendez A.J. Short interfering RNA (siRNA) as a novel therapeutic // Clin Exp Pharmacol Physiol. 2006. — Vol.33. — P.504−510.
- Qian J., Wang Y., Lin J., Yao D., Xu W., Wu Ch. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloidleukemia // European Journal of Haematology. 2008. — Vol.82. — P. 119−123.158
- Quintas-Cardama A., Cortes J. Molecular biology of bcr-abll-positive chronic myeloid leukemia // Blood. 2009. — Vol.113, № 8. — P. 1619 — 1630.
- Quintas-Cardama A., Kantarjian H., Cortes J. Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia // Cancer Control. 2009. — Vol.16, № 2. — P. 122−131
- Ramkissoon S.H., Mainwaring L.A., Ogasawara Y., Keyvanfar K., McCoy J.P. Jr, Sloand E.M., Kajigaya S., Young N.S. Hematopoietic-specific microRNA expression in human cells // Leukemia Research. 2006. -30:643−647.
- Richards S.M., Apperley J., Carella A., et al. Autografting in chronic myeloid leukemia: a metaanalysis of six randomized trials // Haematologica. -2005. -Vol. 90 (Suppl 2): 152−3
- Roeder I., Horn M., Glauche I., et al. Dynamic modeling of imatinib treated chronic myeloid leukemia: functional insights and clinical implications // Nat Med. 2006. — Vol.12, № 10. — P. l 181−1184.
- Roman-Gomez J., Jimenez-Velasco A., Agirre X., Castillejo J. A., Navarro G. Epigenetic regulation of PRAME gene in chronic myeloid leukemia // Leukemia Research. 2007. — Vol.31. — P. 1521−1528.
- S. Brown-Shimer, K.A. Johnson, J.B. Lawrence, C. Johnson, A. Bruskin, N.R. Green, D.E. Hill, Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase IB // Proc. Natl. Acad. Sci. U.S.A. 1990. — 5148−5152.
- Sanchez-Beato M., Sanchez-Aguilera A., Piris M.A. Cell cycle deregulation in B-cell lymphomas // Blood. 2003. — 101:1220−1235.
- Savona M., Talpaz M. Getting to the stem of chronic myeloid leukaemia // Nat Rev Cancer. 2008. — Vol.8. — P.341−350.
- Schaid D.J. The complex genetic epidemiology of prostate cancer // Hum. Mol. Genet.-2004.- 13.-R103-R121.
- Schimanski C.C., Frerichs K., Rahman F., et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells // World J Gastroenterol. 2009. — 15:2089−2096.
- Schlesselman J., Case-control studies. Design, conduct, analysis // New York, Oxford: Oxford University Press. 1982. — P.58−96.
- Sessions J. Chronic Myeloid Leukemia in 2007 // J Manag Care Pharm. -2007. Vol.13. — Suppl S-a: S4-S7.
- Shafi G., Jamil K., Kapley A. et al.RNAi as a novel therapeutic platform technology for oncological solutions // Biotechnology and Molecular Biology Review. 2008. — 4(4):55−70.
- Shannon K.M., O’Connell P., Martin G.A., et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. -N Engl J Med. 1994. — 330:597−601.
- Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. — 2007. — 21:3214−3231.
- Shimkin M.B., Mettier S.R., Bierman H.R. Myelocytic leukemia: An analysis of incidence distribution and fatality // Ann Intern Med. 1951. -Vol. 35.-P.194.
- Side L., Taylor B., Cayouette M., Conner E., Thompson P., Luce M.,
- Shannon K. Homozygous inactivation of the NF1 gene in bone marrow cells160from children with neurofibromatosis type 1 and malignant myeloid disorders // N Engl J Med. 1997. — 336:1713−1720.
- Sokal J.E., Leong S.S., Gomez G.A. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia // Cancer. 1987. -99.- 197.
- Song L., Liu H., Gao S., Jiang W., Huang W. Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells // J Virol. 2010. -84(17):8849−8860.
- Soverini S., Martinelli G., Amabile M., et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib // Clin Chem. 2004. — 50:1205−1213.
- Srikantan V., et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer // Proc. Natl.Acad.Sci.U.S.A. 2000. — 97:12 216−12 221.
- Stanglmaier M., Warmuth M., Kleinlein I., et al. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains // Leukemia. 2003. — Vol.17, № 2. — P.283−289.
- Talpaz M., Silver R.T., Druker B. J, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study // Blood. 2002. — 99. -1928.
- Tang C., Schafranek L., Watkins D.B., Parker W.T., Moore S., Prime J.A., White D.L., Hughes T.P. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways // Leuk Lymphoma. 2011. — 52(11):2139−47.
- Tanzer A., Amemiya C.T., Kim C.B., et al. Evolution of microRNAs located within Hox gene clusters // J Exp Zool B Mol Dev Evol. 2005. — 304: 75−85.
- Thomas J., Wang L., Clark R.E., et al. Active transport of imatinib into and out of cells: implications for drug resistance // Blood. 2004. — Vol.104, № 12. -P.3739−3745.
- Uhm K., Lee E.S., Lee Y.M., et al. Differential Methylation Pattern of ID4, SFRP1, and SHP1 between Acute Myeloid Leukemia and Chronic Myeloid Leukemia // J Korean Med Sci. 2009. — Vol.24. — P.493−497.
- Upadhyaya M. et al. NF1 gene structure and NF1 genotype/phenotype correlations // Neurofibromatoses. Edited by D Kaufmann. Basel, Karger. -2008.-P. 46−62.
- Van Etten R.A. Cycling, stressed-out and nervous: cellular functions of c-Abl // Trends Cell Biol. 1999. — 9:179.
- Venturini L., Battmer K., Castoldi M., Schultheis B., Hochhaus A., Muckenthaler M.U., Ganser A., Eder M., Scherr M. Expression of the miR-17−92 polycistron in chronic myeloid leukemia (CML) CD34+ cells // Blood 2007.- 109:4399−405.
- Wang Y.X., Zhang X.Y., Zhang B.F., et al. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis // J Dig Dis.-2010.- 11:50−54.
- Wendel H.G., de Stanchina E., Cepero E., et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition // Proc Natl Acad Sci U S A. -2006. Vol.103, № 19. — P.7444−7449.
- White, D.L. et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib // Blood. 2006. -108:697−704.
- Wilda M., Fuchs U., Wossmann W., Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi) // Oncogene. -2002. Vol.21. — P.5716 — 5724.
- Witts L.J., et al. Report of the Medical Research Council’s Working Party for Therapeutic Trials in Leukemia: Comparison of radiotherapy and busulphan therapy // Br Med J. 1968. — Vol. 1. — P. 201.
- Woltering J.M., Durston A.J. MiR-10 represses HoxBla and HoxB3a in zebrafish // PLoS ONE. 2008. — 3: el396.
- Woodford-Thomas T.A., Rhodes J.D., Dixon J.E. Expression of a protein tyrosine phosphatase in normal and v-src-transformed mouse 3T3 fibroblasts // J. Cell Biol. 1992.- 117:401−414.
- Wu J., Meng F., Lu H., et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells // Blood. 2008. — Vol.111, № 7. — P.3821−3829.
- Yekta S., Shih I.H., Bartel D.P. MicroRNAdirected cleavage of HOXB8 mRNA // Science. 2004. — 304: 594−596.
- Yi R., Fuchs E. MicroRNA-mediated control in the skin // Cell Death Differ. -2010.-17:229−235.
- Yi R., Poy M.N., Stoffel M. et al. A skin microRNA promotes differentiation by repressing 'sternness'//Nature. 2008. — 452:225−229.
- Zhang B.H. et al. Plant microRNA: a small regulatory molecule with big impact // Dev.Biol. 2006. — 289:3−16.